18th HIV Drug Resistance Workshop

Conference Reports for NATAP


18th HIV Drug Resistance Workshop Ft Myers Florida June 9-12 2009

	HIV Reservoirs and Potential Eradication - Written by Mark A. Wainberg, Ph.D. Professor and Director, McGill University AIDS Centre (06/26/09) PERSISTENCE, RESERVOIRS AND ELIMINATION STRATEGIES - Reported by David Margolis, University of North Carolina (06/26/09) Pre-Existing Low-Levels of the K103N HIV-1 RT Mutation Above a Threshold is Associated with Virological Failure in Treatment-Naïve Patients Undergoing EFV-Containing Antiretroviral Treatment (06/16/09) Bulk sequence-detectable resistance mutations in peripheral RNA following single-dose nevirapine are associated with poorer treatment responses but do not adequately explain treatment failure (06/26/09) Addition of extended zidovudine to extended nevirapine prophylaxis reduces resistance in infants who were HIV-infected in utero: the PEPI- Malawi Study - (06/28/09) Resistance mutations detected by OLA of HIV-1 DNA at the initiation of nevirapine containing ART are associated with virologic failure - (06/28/09) CCR5 Tropism Genotype vs Trofile - (06/27/09) Virco: Population and clonal tropism phenotyping of clinical isolates and comparison with next generation sequencing and prediction tools - (06/27/09) Quest Tropism Assay: Performance of an HIV-1 Co-receptor Tropism Assay Utilizing Replicate V3 Loop Sequencing and Heteroduplex Analysis with Capillary Electrophoresis - (06/27/09) Virco: Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays - (06/27/09) Phenotypic Resistance and Response to Tipranavir, evidence for Hypersusceptibility (06/19/09) Emergence of mutations and phenotypic resistance with tipranavir treatment in protease inhibitor experienced patients (06/19/09) Tipranavir & Darunavir, Prevalences of mutations in patients with discordant phenotypic resistance from Monogram Biosciences database of routine clinical samples from 2006 - 2008 (06/19/09) Tipranavir - Phenotypic protease inhibitor resistance in the clinic from 2006 to 2008: available treatment options (06/19/09) Genotypic, Phenotypic and Virtual Phenotypic Resistance Patterns for Darunavir and Tipranavir: An Independent Analysis of a Quebec HIV-1 Cohort Highly Resistant to all Other Protease Inhibitors (06/17/09) Amino Acid Changes in gp41 of HIV-1 Associated with Coreceptor Tropism (06/17/09) Transitions from CCR5 to CXCR4 use in the absence of antiretroviral drug pressure proceed incrementally and may occur through a multitude of genetic pathways: Monogram Report, Vs loop changes vary (06/17/09) PI-Resistant Virus Seems More Prone to Emergence of Bevirimat Mutations - written by Mark Mascolini (06/16/09) Genotypic and Phenotypic Weighted Optimized Background Therapy Susceptibility Scores Are Similarly Strong Predictors of Virologic Response <50 Copies/mL at Week 48 in MOTIVATE 1 and 2 (06/16/09) 48-Week Results From the Phase 3 Study A4001026 (MERIT) -"Time to Loss of Virologic Response" Virology Analysis of Failures in the Enhanced Trofile®-Censored Subpopulation (06/16/09) High -Prevalence of bevirimat resistance mutations in non-B subtypes and in PI resistant HIV isolates (06/16/09) Resistance Mutations in the Viral Protease Alter Bevirimat Resistance Patterns in vitro (06/16/09) Prevalence and Clinical Significance of Transmitted Drug Resistant HIV Mutations by Ultra-Deep Sequencing in HIV-Infected ARV-Naïve Subjects in the CASTLE Study (06/16/09) Confirmation of the negative impact of protease mutations I47V, I54M, T74P and I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavir (06/16/09) Swiss Cohort Analysis Reveals Clusters of Transmitted Resistant HIV: "make sure patient names remain unlinked to transmission analyses" - written by Mark Mascolini - (06/16/09) Low-Level K103N in Primary Infection Can Reappear After Suppressive Therapy - written by Mark Mascolini - (06/16/09) CCR5 and CCR5 Screening Assays Comparisons: genotype, 454 Ultra-Deep Sequencing and Trofile (06/15/09) Screening for HIV Tropism Using Population-Based V3 Genotypic Analysis: A Retrospective Virological Outcome Analysis Using Stored Plasma Screening Samples From MOTIVATE 1 (06/15/09) In-vitro resistance profile of TMC278, a next-generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first-generation NNRTIs (06/15/09) Weighted Genotype and Phenotypic Scores Predict Response to Maraviroc - written by Mark Mascolini - (06/15/09) Key Etravirine Mutations Also Render HIV Resistant to Rilpivirine - written by Mark Mascolini - (06/15/09) STD History Tied to Infection With Resistant HIV in San Francisco - written by Mark Mascolini - (06/15/09) Low-Level Etravirine Mutations With K103N After NNRTI Failure - written by Mark Mascolini - (06/15/09) Low-Level Q148R in People Without Integrase Inhibitor Experience - written by Mark Mascolini - (06/15/09) Evolving Mutation Patterns Traced During Elvitegravir Failure - written by Mark Mascolini - (06/15/09) Rising Rates of 3-Class Exposure But Falling Failure Rate in US Cities - written by Mark Mascolini - (06/15/09) Transmitted Multidrug-Resistant HIV Persists in PBMC DNA for Years - written by Mark Mascolini - (06/15/09) The HIV-1 RT Mutant Q151L Shows Decreased Replication Capacity, Selective High-Level Resistance to GS-9148 and Hypersusceptibility to Tenofovir and Zidovudine - (06/15/09) HBV Resistance to Lamivudine at Undetectable and Low Levels of Viremia - written by Mark Mascolini - (06/15/09) Early Response to Maraviroc Equivalent With Coreceptor Genotyping and Trofile Phenotyping - written by Mark Mascolini - (06/15/09) Most Low-Level Pretreatment Mutations Did Not Affect Outcome in PI Trial - written by Mark Mascolini - (06/15/09) Cutoffs Suggested for Predicting Efavirenz Failure With Low-Level K103N - written by Mark Mascolini - (06/15/09) Regimens Lacking CCR5 Antagonists Have Minimal Impact on Coreceptor Use - written by Mark Mascolini - (06/12/09) Lower M184V Rates With FTC/TDF Than With 3TC/TDF - written by Mark Mascolini - (06/12/09) Raltegravir Did Not Lower HIV DNA Levels in Cell Reservoirs in Salvage Patients in 24 Weeks - written by Mark Mascolini - (06/12/09) Intensification of Already Suppressive Therapy with Raltegravir Had No Impact on Low-Level (sub-50-copy) Viremia - written by Mark Mascolini - (06/12/09) HIV Genetic Diversity Does Not Change Much After Complete Viral Control - written by Mark Mascolini - (06/12/09) NNRTI/PI Regimen More Prone to Resistance Than Standard Triple Combos - written by Mark Mascolini - (06/12/09) Success Rate With Genotype-Guided First Regimen Near 90% in California - written by Mark Mascolini - (06/12/09)